PAZOPANIB HYDROCHLORIDE

Post-LOE

pazopanib hydrochloride

Novartis

ANDAORALTABLET

Approved

Sep 2025

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

3/8 — Basic

PAZOPANIB HYDROCHLORIDE (pazopanib hydrochloride) by Novartis is multi-tyrosine kinase inhibitor of vascular endothelial growth factor receptor (vegfr)-1, vegfr-2, vegfr-3, platelet-derived growth factor receptor (pdgfr)-α and -β, fibroblast growth factor receptor (fgfr)-1 and -3, cytokine receptor (kit), interleukin-2 receptor-inducible t-cell kinase (itk), lymphocyte-specific protein tyrosine kinase (lck), and transmembrane glycoprotein receptor tyrosine kinase (c-fms). First approved in 2025.

Drug data last refreshed 18h ago

Mechanism of Action

multi-tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, VEGFR-3, platelet-derived growth factor receptor (PDGFR)-α and -β, fibroblast growth factor receptor (FGFR)-1 and -3, cytokine receptor (Kit), interleukin-2 receptor-inducible T-cell kinase (Itk),…

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Clinical Trials (5)

NCT03334409Phase 2Terminated

Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery

Started Feb 2018

5 enrolled

Clear Cell Renal Cell CarcinomaMetastatic Clear Cell Renal Cell CarcinomaStage III Renal Cell Cancer AJCC v8+2 more

NCT02357810Phase 2Completed

Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas

Started Mar 2015

178 enrolled

Adult LiposarcomaMetastatic LiposarcomaMetastatic Osteosarcoma+4 more

NCT01684397Phase 1/2Active Not Recruiting

Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer

Started Nov 2012

51 enrolled

Clear Cell Renal Cell CarcinomaStage IV Renal Cell Cancer

NCT01465659Phase 1/2Completed

Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery

Started Dec 2011

29 enrolled

Pancreatic Alpha Cell CarcinomaPancreatic Beta Islet Cell CarcinomaPancreatic Delta Cell Carcinoma+2 more

NCT01413113Phase 1Completed

Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery

Started Dec 2011

6 enrolled

Recurrent Thyroid CancerStage IVA Follicular Thyroid CancerStage IVA Papillary Thyroid Cancer+4 more

Worked on PAZOPANIB HYDROCHLORIDE at Novartis? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.